Screening for Clostridium difficile Carriers at Hospital Admission Reduces Subsequent C. difficile Infections
By Richard R. Watkins, MD, MS, FACP
Associate Professor of Internal Medicine, Northeast Ohio Medical University; Division of Infectious Diseases, Cleveland Clinic Akron General Medical Center, Akron, OH
Dr. Watkins reports that he has received research support from Actavis.
SYNOPSIS: Patients admitted to a single hospital were screened for C. difficile carriage and those found to be positive were placed in contact isolation. This led to a significant decrease in hospital-acquired C. difficile infections.
SOURCE: Longtin Y, et al. Effect of detecting and isolating Clostridium difficile carriers at hospital admission on the incidence of C. difficile infections: A quasi-experimental controlled study. JAMA Intern Med. 2016;176:796-804.
Clostridium difficile infection (CDI) is now the leading nosocomial infection in the United States. Novel approaches are needed to decrease the CDI epidemic. Longtin and colleagues reported the results of one such strategy: identifying and isolating asymptomatic carriers of C. difficile.
The study was conducted at a single institution in Quebec City, Canada, that had been experiencing a high burden of hospital-acquired CDI (HA-CDI). Patients admitted through the emergency department underwent screening for C. difficile by rectal swabs that identified the tcdB gene by polymerase chain reaction. C. difficile carriers then were placed into modified isolation similar to what is done for cases of CDI but with some modifications, including not requiring healthcare workers to wear isolation gowns and allowing carriers to share a room with non-carriers. For logistical reasons, patients admitted directly to the wards and those who stayed less than 24 hours were excluded. The primary outcome was the change in incidence rate of HA-CDI per 10,000 patient-days after implementation of the intervention. Secondary outcomes included changes in the proportion of HA-CDI cases with complications and changes in strain types causing CDI. The control used for the study was the HA-CDI incidence rates from other institutions in Quebec during the same time course.
The average incidence rate of HA-CDI before the intervention was 8.2 per 10,000 patient-days. After the intervention, the incidence rate decreased to 3.0 per 10,000 patient-days (P < 0.001). Out of 7,599 eligible patients who were screened, 368 (4.8%) were found to be asymptomatic carriers. There were no significant differences in complications (i.e., 10- and 30-day all-cause mortality, admission to the intensive care unit, need for colectomy, or readmission for recurrent CDI) between the pre-intervention and post-intervention periods (P > 0.05 for all). Forecast modeling estimated that the intervention prevented 63 of 101 expected cases of HA-CDI, while there was no significant change detected in the control group. Furthermore, there was a significant decrease in the proportion of NAP1 strains after the intervention compared to beforehand (2 of 10 strains [20%] vs. 45 of 76 [59%], respectively; P < 0.049). No corresponding decrease in NAP1 strains was observed in the other hospitals in Quebec City during the intervention period (80% of C. difficile strains were NAP1). Notably, there also were outbreaks of influenza, viral gastroenteritis, and carbapenemase-producing Enterobacteriaceae during the intervention period at the study institution. Efforts to improve hand hygiene were introduced to mitigate the outbreaks. Consequently, the hand hygiene rate improved from 36.6% to 49.7%.
This study showed how a relatively simple intervention (i.e., rectal swabs that detect C. difficile followed by isolation of carriers) could have a significant impact on the burden of CDI in an inpatient setting. Before the intervention, the study institution had a high burden of HA-CDI. Afterward, it had the lowest incidence rate of HA-CDI among the 22 academic hospitals in Quebec. Experts believe that despite not having diarrhea, asymptomatic carriers of C. difficile still shed spores that contaminate the environment and get on caregivers’ hands. This environmental contamination is particularly troublesome for institutions that do not have all private rooms.
Although the results were impressive, the study raises important economic questions. For example, do the cost savings from preventing HA-CDI exceed the cost of the intervention? The investigators attempted to address this issue by noting that each case costs $3,427 to $9,960 and since it was calculated that the intervention prevented 63 cases, the savings from averting HA-CDI ($216,000 to $627,000) exceeded the cost of the intervention ($130,000). However, further cost-analysis studies that include multiple sites are needed to determine if these savings can be replicated in other settings. Another issue to be elucidated is whether the intervention would have a significant impact at an institution that does not have a high incidence of HA-CDI. In this setting, the cost of the intervention might not be justified, although the public reporting of HA-CDI rates might nonetheless motivate hospital administrators to pay for it.
There were a couple of limitations to the study worth mentioning. The authors did not assess how many of the asymptomatic carriers had a previous history of CDI. Also, the institutional hand hygiene compliance improved during the study, which may have falsely inflated the benefit of the intervention. On the other hand, the improvement was quite modest, going from 37% to a rather dismal 50%. Institutional antibiotic stewardship also might have played a confounding role by limiting antibiotics that are most associated with HA-CDI, such as clindamycin and quinolones. Despite these limitations, isolating asymptomatic carriers of C. difficile seems like a promising strategy that should be investigated with larger clinical trials.
Patients admitted to a single hospital were screened for C. difficile carriage and those found to be positive were placed in contact isolation. This led to a significant decrease in hospital-acquired C. difficile infections.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.